Search Results 111-120 of 16572 for Valproate
... valproate), and somatostatin receptor ligands (octreotide long-acting release [LAR], pasireotide LAR, lanreotide). Concomitant use of the following due to ...
Onasemnogene abeparvovec-brve injection is used to treat spinal muscular atrophy (SMA) with confirmed mutation in survival motor neuron 1 (SMN1) gene. Spinal ...
Bipolar I participants must be on conventional mood stabilizing treatment [lithium, divalproex or valproate, or an atypical antipsychotic]. Participants ...
... Valproate, Gabapentin, Pregabalin, tiagabine, and vigabatrin) are prohibited within two weeks prior to administration of study drug and at least 24 hours ...
We did the genetic testing and found out, in fact, Andrew was not able to break down the medications the way most individuals would. Because of this, the ...
Patient is willing and clinically is appropriate to pursue treatment with lithium, lamotrigine, or valproate for treatment of bipolar I or II depression.If ...
Medication use with epigenetic properties (hydroxychloroquine, methotrexate, 5-azacitidine, valproate, or levofloxacin) at time of enrollment or prior 3 weeks.
... valproate (Depakote), or zonisamide (Zonegran), vigabatrin (Sabril)]. Participating Mayo Clinic locations. Study statuses change often. Please contact the ...
Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet ...
Within 4 weeks of Screening (first visit), concurrent treatment with antipsychotic agents or mood stabilizers (e.g., valproate, lithium) or benzodiazepines, ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.